BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

Author: Ben Comer February 2, 2026 Duration: 44:35

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and the FDA's selection of zongertinib (in patients with HER2-mutant NSCLC) for the Commissioner's National Priority Voucher program.    

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
BoB@JPM: Ron Cooper, enGene [not-audio_url] [/not-audio_url]

Duration: 55:57
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at…
BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics [not-audio_url] [/not-audio_url]

Duration: 36:08
We love to hear from our listeners. Send us a message. The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO…
A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith [not-audio_url] [/not-audio_url]

Duration: 58:44
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therap…